Senior insider sale
Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. — senior position signals high conviction
$23.14M
347.06K shares
What this filing means
ANZALONE CHRISTOPHER RICHARD plans to sell 347.06K shares of ARROWHEAD PHARMACEUTICALS, INC. valued at approximately $23.14M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 12/29/2025ACC: 0001628280-25-058998
DirectorOfficer· Chief Executive Officer
Since Aug 2018
347.06K
Shares to sell
$23.14M
Approx. market value
51.73K
Acquired (3 months)
1
Planned
5 completed
Securities Acquired — Last 3 Months1
Compensation
Compensation
1/1/2016
51.73KTotal acquired51.73K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/1/2016 | Compensation Compensation | 51.73K | — |
| Total | 51.73K | ||
Planned & Completed Dispositions6
Completed
—Completed
Units to sell
12.59K
Market value
$861.4K
12/22/2025
—Completed
Units to sell
13.45K
Market value
$909.6K
12/19/2025
—Completed
Units to sell
85K
Market value
$5.44M
12/17/2025
—Completed
Units to sell
54.30K
Market value
$3.40M
12/16/2025
—Completed
Units to sell
130K
Market value
$8.95M
12/15/2025
Planned — Approximate Date
NASDAQPlanned
Units to sell
51.73K
Market value
$3.58M
12/29/2025
Total
Units
347.06K
Value
$23.14M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
12/22/2025 | 12.59K | $861.4K | — | Completed |
12/19/2025 | 13.45K | $909.6K | — | Completed |
12/17/2025 | 85K | $5.44M | — | Completed |
12/16/2025 | 54.30K | $3.40M | — | Completed |
12/15/2025 | 130K | $8.95M | — | Completed |
| Planned — Approximate Date | ||||
12/29/2025 | 51.73K | $3.58M | NASDAQ | Planned |
| Total | 347.06K | $23.14M | ||